Literature DB >> 29544233

[Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State].

Christina Schumann, Michael Faust.   

Abstract

BACKGROUND: Diabetic ketoacidosis and the hyperosmolar hyperglycemic state are the most serious diabetic emergencies. Before the discovery of insulin in 1921 by Banting and Best the diagnosis of type 1 diabetes was fatal ending in diabetic ketoacidosis equivalent to a torturous death. Today, mortality from diabetic ketoacidosis is low at approximately 2 %. But each death from these two acute metabolic complications of diabetes is potentially avoidable by improved patient and healthcare professional education. Therefore, there is a need to raise awareness of hyperglycemic crisis and its management amongst physicians. PATHOGENESIS: Insulin deficiency or resistence and increased concentrations of counterreulatory hormones (glucagon, catecholamines, cortisol and growth hormone) are responsible for the development of diabetic ketoacidosis and the hyperosmolar hyperglycemic state. Hyperglycemia develops as a result of increased gluconeogenesis and accelerated glyconeogenesis. In DKA, the absolute insulin deficiency additionally leads to increased lipolysis and production of ketone bodies and resulting metabolic acidosis. DIAGNOSIS: Both DKA and HHS require prompt recognition and management. The diagnosis can be suspected by clinical features and confirmed by laboratory findings. TREATMENT: The treatment of DKA and HHS is similar, including correction of fluid and electrolyte abnormalities and the administration of insulin. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 29544233     DOI: 10.1055/s-0043-114493

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  1 in total

1.  EXPRESSION AND ACTIVITY OF AMINOTRANSFERASES IN THE LIVER OF STREPTOZOTOCIN-DIABETIC RATS: THE EFFECT OF MIFEPRISTONE.

Authors:  V G Selyatitskaya; N Palchikova; A Tsidulko; O I Kuzminova
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.